Advertisement
Incyte Corporation (INCY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
At close: 04:00PM EDT
After hours:
| Previous Close | 66.43 |
| Open | 66.41 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 65.91 - 66.95 |
| 52 Week Range | 50.27 - 70.36 |
| Volume | |
| Avg. Volume | 1,911,898 |
| Market Cap | 12.787B |
| Beta (5Y Monthly) | 0.74 |
| PE Ratio (TTM) | 161.93 |
| EPS (TTM) | 0.41 |
| Earnings Date | Oct 29, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 73.95 |
GlobeNewswireKnight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico
MONTREAL, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. has obtained regulatory approval by COFEPRIS, the Mexican health regulatory agency, for Minjuvi® (tafasitamab) in combination with lenalidomide followed by Minjuvi® monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cel
Business WireIncyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
WILMINGTON, Del., October 10, 2024--Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.